NATAN DAVID

SEC source: 0001683168-26-006206 · ownership.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,300

F1 · kind: Represents a stock award to the reporting person.

SEC source: 0001213900-26-085336 · ownership.xml · derivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,840

Underlying: Ordinary Shares · 190,840 shares

Expires 2036-08-03

F1 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates.

SEC source: 0001213900-26-086313 · ownership.xml · derivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,860

Underlying: Ordinary Shares · 191,860 shares

Expires 2036-08-03

F1 · date: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction.

F1 · shares: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction.

F2 · derivative.exercise_date: The Stock Options will vest in eighteen substantially equal installments on each monthly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates.

F1 · derivative.underlying_shares: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction.

F1 · balance_after: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, (iii) the number of shares underlying the securities acquired by the Reporting Person, and (iv) the quantity of securities beneficially owned by the Reporting Person following the reported transaction.

SEC source: 0001213900-26-060214 · ownership.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,141

SEC source: 0001829126-26-004759 · ownership.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 248,792

F1 · kind: Represents an award of common stock issued pursuant to the Director Agreement dated April 29, 2025.

F2 · balance_after: The reported amount reflects a corrective adjustment to the Reporting Person's prior filings to account for an under-reporting of 2,000 shares of beneficial ownership attributable to a clerical error.

SEC source: 0001683168-26-002922 · ownership.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

F1 · kind: Represents a stock award to the reporting person.

SEC source: 0001829126-26-003045 · ownership.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 276,876

F1 · shares: 26,876 shares issued as non-employee director compensation and 250,000 shares issued as compensation for services as an advisor to the Company.

SEC source: 0001493152-26-003292 · ownership.xml · derivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2036-01-07

F1 · derivative.exercise_date: The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Issuer's board of directors through each vesting date.

SEC source: 0000921895-25-000652 · form412227019nat_02282025.xml · derivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2035-02-26

F1 · shares: On February 26, 2025 (the "Grant Date"), the Reporting Person was granted 700,000 Non-Qualified Stock Options to purchased shares of common stock (the "Common Stock") of Cyclacel Pharmaceuticals, Inc. (the "Company") in consideration of his services as a director of the Company. The option grant became exercisable on the Grant Date.

F2 · shares: Includes shares of Common Stock previously reported in Table I of the Reporting Person's Form 4 filed on January 7, 2025, which were not issued by the Company and are being replaced with the option grant reported in this Form 4.

F1 · price: On February 26, 2025 (the "Grant Date"), the Reporting Person was granted 700,000 Non-Qualified Stock Options to purchased shares of common stock (the "Common Stock") of Cyclacel Pharmaceuticals, Inc. (the "Company") in consideration of his services as a director of the Company. The option grant became exercisable on the Grant Date.

F1 · derivative.exercise_date: On February 26, 2025 (the "Grant Date"), the Reporting Person was granted 700,000 Non-Qualified Stock Options to purchased shares of common stock (the "Common Stock") of Cyclacel Pharmaceuticals, Inc. (the "Company") in consideration of his services as a director of the Company. The option grant became exercisable on the Grant Date.

SEC source: 0000921895-25-000087 · form412227001_01072025.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

F1 · price: Shares of restricted stock issued pursuant to a Director Agreement dated as of January 2, 2025 by and between Cyclacel Pharmaceuticals, Inc. and David Natan.

SEC source: 0000921895-24-002197 · form412227016nat_10012024.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,792

F1 · price: Shares of restricted stock issued pursuant to the Non-Employee Directors Compensation Plan of Minim, Inc.

SEC source: 0000921895-24-000831 · form412227017nat_04122024.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

F1 · price: Shares of restricted stock issued pursuant to the 2015 Equity Incentive Plan of OpGen, Inc.

SEC source: 0000921895-24-000129 · form412227016nat_01242024.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

F1 · price: Shares of restricted stock issued pursuant to the Non-Employee Directors Compensation Plan of Minim, Inc.

SEC source: 0000921895-23-002396 · form413531002nat_10262023.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,250

F1 · shares: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.

SEC source: 0000921895-23-001753 · form413531nat_07282023.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.

SEC source: 0000921895-23-001769 · form4a13531001nat_07312023.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.

SEC source: 0000921895-23-001753 · form413531nat_07282023.xml · derivative · entry 3

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2022-09-15

F3 · derivative.exercise_price: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.

F3 · date: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.

F3 · derivative.exercise_date: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.

SEC source: 0000921895-23-001753 · form413531nat_07282023.xml · derivative · entry 2

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2022-08-15

F2 · derivative.exercise_price: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.

F2 · date: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.

F2 · derivative.exercise_date: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.

SEC source: 0000921895-23-001769 · form4a13531001nat_07312023.xml · derivative · entry 3

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-09-15

F4 · derivative.exercise_price: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.

F4 · date: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.

F4 · derivative.exercise_date: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.

F3 · derivative.expiration_date: This Form 4 is being amended to correct the expiration date of the options, which were incorrectly reported in the original report due to an inadvertent clerical error.

SEC source: 0000921895-23-001769 · form4a13531001nat_07312023.xml · derivative · entry 2

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-08-15

F2 · derivative.exercise_price: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.

F2 · date: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.

F2 · derivative.exercise_date: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.

F3 · derivative.expiration_date: This Form 4 is being amended to correct the expiration date of the options, which were incorrectly reported in the original report due to an inadvertent clerical error.

SEC source: 0001493152-22-012990 · ownership.xml · nonDerivative · entry 1

NATAN DAVID · CIK 0001253108 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

F1 · price: These shares were granted to the reporting person as compensation for the services provided to the issuer as a director.